Ascelia Pharma: Just about to submit Orviglance for US approval - Redeye

Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September. The second critical value driver is to secure a US partner for the upcoming launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123807/ascelia-pharma-just-about-to-submit-orviglance-for-us-approval?utm_source=finwire&utm_medium=RSS